• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Epigenetics: official journal of the DNA Methylation Society >DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study
【24h】

DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study

机译：DNA甲基化与乳腺肿瘤的临床病理特征：纽约西部暴露与乳腺癌（WEB）研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We evaluated the association between methylation of 9 genes, SCGB3A1, GSTP1, RARB, SYK, FHIT, CDKN2A, CCND2, BRCA1, and SFN in tumor samples from 720 breast cancer cases with clinicopathological features of the tumors and survival. Logistic regression was used to estimate odds ratios (OR) of methylation and Cox proportional hazards models to estimate hazard ratios (HR) between methylation and breast cancer related mortality. Estrogen receptor (ER) and progesterone receptor (PR) positivity were associated with increased SCGB3A1 methylation among pre- and post-menopausal cases. Among premenopausal women, compared with Stage 0 cases, cases of invasive cancer were more likely to have increased methylation of RARB (Stage I OR = 4.7, 95% CI: 1.1-19.0; Stage IIA/IIB OR = 9.7, 95% CI: 2.4-39.9; Stage III/IV OR = 5.6, 95% CI: 1.1-29.4) and lower methylation of FHIT (Stage I OR = 0.2, 95% CI: 0.1-0.9; Stage IIA/IIB OR = 0.2, 95% CI: 0.1-0.8; Stage III/IV OR = 0.6, 95% CI: 0.1-3.4). Among postmenopausal women, methylation of SYK was associated with increased tumor size (OR = 1.7, 95% CI: 1.0-2.7) and higher nuclear grade (OR = 2.0, 95% CI 1.2-3.6). Associations between methylation and breast cancer related mortality were observed among pre- but not post-menopausal women. Methylation of SCGB3A1 was associated with reduced risk of death from breast cancer (HR = 0.41, 95% CI: 0.17-0.99) as was BRCA1 (HR = 0.41, 95% CI: 0.16-0.97). CCND2 methylation was associated with increased risk of breast cancer mortality (HR = 3.4, 95% CI: 1.1-10.5). We observed differences in methylation associated with tumor characteristics; methylation of these genes was also associated with breast cancer survival among premenopausal cases. Understanding of the associations of DNA methylation with other clinicopathological features may have implications for prevention and treatment.
机译：我们评估了720例乳腺癌病例的肿瘤样本中SCGB3A1，GSTP1，RARB，SYK，FHIT，CDKN2A，CCND2，BRCA1和SFN的9个基因的甲基化与肿瘤的临床病理特征和生存率之间的关联。 Logistic回归用于估计甲基化的风险比（OR）和Cox比例风险模型，以估计甲基化与乳腺癌相关死亡率之间的风险比（HR）。绝经前后病例中雌激素受体（ER）和孕激素受体（PR）阳性与SCGB3A1甲基化增加有关。在绝经前妇女中，与0期患者相比，浸润性癌症患者的RARB甲基化增加的可能性更大（I阶段= 4.7，95％CI：1.1-19.0; IIA / IIB阶段= 9.7，95％CI： 2.4-39.9;阶段III / IV OR = 5.6，95％CI：1.1-29.4）和较低的FHIT甲基化程度（阶段I OR = 0.2，95％CI：0.1-0.9; IIA / IIB阶段OR = 0.2，95％ CI：0.1-0.8;阶段III / IV OR = 0.6，95％CI：0.1-3.4。在绝经后妇女中，SYK甲基化与肿瘤大小增加（OR = 1.7，95％CI：1.0-2.7）和更高的核分级（OR = 2.0，95％CI 1.2-3.6）相关。在绝经前妇女中观察到甲基化与乳腺癌相关死亡率之间的关联。 SCGB3A1的甲基化与乳腺癌死亡风险降低有关（HR = 0.41，95％CI：0.17-0.99），而BRCA1（HR = 0.41，95％CI：0.16-0.97）也是如此。 CCND2甲基化与乳腺癌死亡风险增加相关（HR = 3.4，95％CI：1.1-10.5）。我们观察到甲基化与肿瘤特征相关的差异。这些基因的甲基化还与绝经前病例中的乳腺癌存活率有关。了解DNA甲基化与其他临床病理特征的关联可能对预防和治疗有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号